Segment Information

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply our products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s CODM is the Chief Executive Officer, who assesses performance and allocates resources based on the significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which are cash and cash equivalents, current restricted cash, and short-term investments) that are also reported on the consolidated balance sheets when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.

The following tables present disaggregated expenses that are regularly provided to the CODM:

	Three Months Ended March 31,
	2025	2024
Personnel compensation and related costs	24,079	28,008
Licensing fees	19,997	—
CROs/CMOs/Investigators expenses	9,830	19,904
Other costs	6,823	6,733
Total research and development expenses	60,729	54,645

	Three Months Ended March 31,
	2025	2024
Clinical programs	28,092	18,788
Pre-Clinical programs	3,314	2,049
Unallocated research and development expenses	29,323	33,808
Total research and development expenses	60,729	54,645

	Three Months Ended March 31,
	2025	2024
Personnel compensation and related costs	40,643	45,894
Other costs	22,779	23,300
Total selling, general, and administrative expenses	63,422	69,194

	Three Months Ended March 31,
	2025	2024
Selling and marketing expenses	41,939	43,594
General and administrative expenses	21,483	25,600
Total selling, general, and administrative expenses	63,422	69,194